Kimia Biosciences Ltd

Extreme leverage (D/E 9.69) leaves no margin for operational disruption; aggregate ROE -91.89% shows ongoing capital destruction despite recent profitable quarters.

Revenue volatility ₹23.58–₹38.24 Cr across recent quarters; Mar 2026 fell to ₹27.2 Cr — verify operational consistency and whether swings reflect customer concentration or market instability.

Zero FII interest (0%), minimal DII (0.38%), 74.94% promoter holding — illiquid, uninstitutionalized; market skepticism about returns or governance evident.

Verify if recent profitability (Dec 2025: 21.78% OPM; Mar 2025: 21.39% OPM) represents structural recovery or cyclical gains masking capital-destroying fundamentals.

Dec 2025 achieved 21.78% OPM and ₹5.44 Cr profit; Mar 2025 hit 21.39% OPM and ₹1.99 Cr profit — if repeatable, implies ₹70+ Cr annualized earnings; verify if structural or tied to product mix/pricing timing.

Sep 2025 revenue ₹34 Cr (highest recent quarter); at 7–11% OPM baseline, yields ₹2.4–3.7 Cr quarterly profit — verify what drove Sep volume and whether momentum continues.

If quarterly revenue grows from current ₹27–₹34 Cr range to ₹40–50 Cr while debt service stays fixed, unit economics improve — verify whether product demand and market position support this growth path.

Indian pharma sector fundamentals (aging population, health spending growth) — verify company's therapeutic focus, competitive positioning, and addressable market-share opportunity.